SEC 10Q
enGene Therapeutics 10-Q Reveals $45M Cash Burn, R&D Spend Up 32% YoY, and No Revenue — Clinical Timeline Critical
enGene Therapeutics' 10-Q for the quarter ended July 31, 2026, reveals a deteriorating cash position with only $45.2M in cash, a quarterly burn of ~$16.7M, and a going concern uncertainty. The company has no approved products and relies on collaboration revenue of just $0.5M in the quarter. R&D spending increased 32% YoY to $12.3M, reflecting aggressive investment in the lead candidate DETAIL, but the company's net loss widened to $18.9M. The recent $20M private placement provides some relief but is insufficient to fund operations beyond the next two quarters, forcing the company to seek additional capital or partnerships. The key catalyst is the interim efficacy data from the DETAIL Phase 2/3 trial, expected in Q1 2027, which could either validate the platform or lead to a significant decline. The company's warrants (ENGNW) may provide incremental cash if exercised, but this is contingent on stock price appreciation. Given the high burn rate and no near-term revenue, the stock is likely to face downward pressure unless clinical milestones are met.
- Ticker
- ENGN
- Form
- 10-Q
Filing analysis
enGene Therapeutics' 10-Q for the quarter ended July 31, 2026, reveals a deteriorating cash position with only $45.2M in cash, a quarterly burn of ~$16.7M, and a going concern uncertainty. The company has no approved products and relies on collaboration revenue of just $0.5M in the quarter. R&D spending increased 32% YoY to $12.3M, reflecting aggressive investment in the lead candidate DETAIL, but the company's net loss widened to $18.9M. The recent $20M private placement provides some relief but is insufficient to fund operations beyond the next two quarters, forcing the company to seek additional capital or partnerships. The key catalyst is the interim efficacy data from the DETAIL Phase 2/3 trial, expected in Q1 2027, which could either validate the platform or lead to a significant decline. The company's warrants (ENGNW) may provide incremental cash if exercised, but this is contingent on stock price appreciation. Given the high burn rate and no near-term revenue, the stock is likely to face downward pressure unless clinical milestones are met.
All ENGN markets, filings and insider activity →
Source: Original SEC filing